Background Few medical studies have clarified the prognostic factors that affect medical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy. International Prognostic Index (aa-IPI). Risk assessment according to SUVmax at relapse The median SUVmax was 10.9 (range, 2.9-33.0). The ideal cut-off for SUVmax was 6.0 according to ROC curve analysis. The area under the ROC curve of SUVmax was 0.811. The level of sensitivity and specificity were 90.1 and 73.1%, respectively. Depending on his or her SUVmax, each patient was classified into either the low (<6.0) or high SUVmax group (6.0). Relating to this cut-off value, significant variations in survival were observed (<0.001 for PFS and <0.001 for OS, Fig. 2A-B). Fig. 2 Assessment of medical outcomes according to a maximum standardized uptake value (SUVmax) cut-off of 6.0. Prognostic factors affecting medical outcomes To examine whether medical outcomes were affected by various prognostic factors (age65 years, low aa-IPI, SUVmax <6.0, time-to-relapse >12 weeks, and CR Telmisartan status after salvage therapy), the factors were analyzed regarding their prognostic significance for salvage therapy. In univariate analysis, a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), time to relapse >12 months (=0.025 for PFS, <0.001 for OS), and CR status after the therapy (=0.002 for PFS, <0.001 for OS) were associated with both PFS and OS (Table 2). Table 2 Univariate analysis of the prognostic factors predicting the Telmisartan medical outcomes. Multivariate analysis revealed that a low aa-IPI (<0.001 for PFS, <0.001 for OS), SUVmax <6.0 (<0.001 for PFS, <0.001 for OS), and time to relapse 12 months (<0.057 for PFS, <0.001 for OS) were indie prognostic factors associated with favorable outcomes (Table 3). Table 3 Multivariate analysis of the prognostic factors predicting the medical outcomes. Conversation Few studies have been devoted to restorative options for individuals with relapsed DLBCL who are ineligible for HDT/ASCT. It is well known the prognosis is extremely poor with few restorative options. The best restorative treatment is definitely palliative chemotherapy together with additional interventions to preserve a high quality of existence. However, some subgroups of relapsed individuals with low risk accomplish a second good response and encounter long term survival. Therefore, it is important to identify prognostic factors for predicting long-term results in this populace. Several studies suggested the medical value of particular prognostic factors including a tumor mass Telmisartan dimensions larger than 10 cm, restorative regimens prior to ASCT, elevated LDH levels, short time to relapse, and an overall high disease burden [9,10,11,12,13,14]. However, the widely approved solitary prognostic model in the relapsed/refractory establishing could not become generalized. A recent study illustrated the prognostic significance of aa-IPI based on the medical data of individuals with relapsed NHL who underwent HDT/ASCT [15,16,17]. Guglielmi et al. also performed a retrospective analysis of aa-IPI factors for individuals with relapsed DLBCL and recognized relapse within 12 months of the initial analysis and aa-IPI factors as significant self-employed prognostic factors [18]. In addition, other medical studies shown the positive predictive value of aa-IPI [3,19,20]. However, Telmisartan these results cannot be generalized to all individuals with NHL because the aa-IPI factors were mostly focused on individuals who underwent HDT/ASCT. Conversely, Rabbit Polyclonal to EGFR (phospho-Ser1026) the present study was designed to evaluate the prognostic value of aa-IPI for individuals with relapsed or refractory DLBCL who were ineligible for HDT/ASCT, and the data suggested that a low aa-IPI is definitely associated with beneficial results for HDT/ASCT-ineligible individuals. Several research organizations have investigated the use of 18F-FDG PET/CT to predict the outcomes of.
Tag Archives: Rabbit Polyclonal to EGFR phospho-Ser1026)
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva